Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 0.00 0.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8526 to 8549 of 8900 messages
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
DateSubjectAuthorDiscuss
11/3/2020
12:28
I would say you made a self-fulfilling prophecy Semper - back to the open!
toffeeman
11/3/2020
12:03
When I say things like that, it is normally too the kiss of death.
semper vigilans
11/3/2020
10:40
Nice to see today's news have an influence on the share price One would also have to say AOR is a very defensive stock in today's market and therefore may at the very least see no major falls.
cocker
11/3/2020
09:45
Our fair value would change to £101.2m or 689p / share (previously £99.2m or 676p / share) on a pro forma basis that takes account of the additional shares issued. The largest components of our valuation remain AorTech’s products which are valued on transaction multiples based on the historical acquisitions of similar products.
someuwin
11/3/2020
09:42
Netcurtains Assuming shareholders approve the deal on 31 March, the name change happens 2april and the ticker about the same time
landy90
11/3/2020
09:39
Following today's proposed acquisition of RUA, new research note published by Dr Andy Smith at Equity Development examining potential of combined group. Seen as a strategically sensible move, fair value of group would edge up too. You can read full analysis here at no charge: https://www.equitydevelopment.co.uk/edreader/?ltkn=[ID]&d=%3D%3DgN5YjM
edmonda
11/3/2020
09:17
When will the ticker change?
netcurtains
11/3/2020
08:36
Great stock to buy dips, same with (PPS), two growth gems imo
ny boy
11/3/2020
08:31
Following Completion, the Company intends to restructure its business into four distinct trading subsidiaries, with AorTech (to be renamed RUA Life Sciences plc) as the holding company. A description of each of the companies is detailed below, all of which will have trading and licence relationships with other companies within the Enlarged Group. RUA Life Sciences The holding company of the Enlarged Group, quoted on AIM, and 100 per cent. owner and controller of each of these four trading subsidiaries, RUA Medical, RUA Vascular, RUA Biomaterials and RUA Structural Heart. RUA Medical Following Completion, RUA Medical will become a wholly owned subsidiary of RUA Life Sciences. It will continue to focus on the development of medical textiles, including soft tissue patches and large bore vascular grafts using a substantial amount of know-how created during its working relationship with AorTech, relating to the multiple manufacturing processes for Elast-Eon(TM) , which, as set out above, include extrusion, dip processing (casting and coating), spray coating (including electro spinning and ultrasonic) and moulding (including compression, injection and reaction injection moulding). It is intended that the business will retain its ISO 13485:2016 certificate and that both cleanroom sites will continue to be FDA registered. The Board's strategy is to retain the RUA Medical business as a third-party design, development and manufacturing house for medical devices, but expand the areas of expertise and product offerings to include Elast-Eon(TM) . RUA Medical will continue to service the requirements of its current and prospective client base whilst also developing and manufacturing devices for other group companies. RUA Vascular Following Completion, Cortech Medical Limited, which was acquired by the Company in June 2018, will be renamed RUA Vascular Limited and it is intended that it will hold the intellectual property relating to the Enlarged Group's cardiovascular and soft tissue patches and large bore vascular grafts. In future, RUA Vascular will purchase the completed grafts and patches from RUA Medical on commercial terms and market them to distributors for onward sale to hospitals and OEM customers for inclusion in other devices. It is planned that RUA Biomaterials will grant RUA Vascular an exclusive licence to incorporate the polymer material into the patches and grafts retaining exclusivity in this field and generating further licence income for RUA Biomaterials. The currently available technology for soft tissue patches and large bore grafts comprises either animal tissue or textile (PTFE) material. Each material is compromised by either suffering from calcification or subject to tissue ingrowth leading to adhesion. Elast-Eon(TM) based products should avoid these problems and address a market that is suffering a lack of supply of animal sourced products. The Company has identified device categories that currently rely on abattoir-sourced animal by-products or textile (PTFE) material. Replacing animal tissue with Elast-Eon(TM) will eliminate animal by-product sourcing risk and improve product sterilisation options and allow end-to-end control over the supply chain. RUA Biomaterials Following Completion, AorTech Biomaterials Limited, a non-trading subsidiary of AorTech, will change its name to RUA Biomaterials and it is planned that it will own the Intellectual Property related to Elast-Eon(TM) and that it will hold all patents and licence agreements relating to Elast-Eon(TM), thereby generating royalty income. It is also intended that it will enter into licence agreements with the other subsidiaries of the Enlarged Group; namely RUA Medical for manufacturing, RUA Vascular and RUA Structural Heart. RUA Biomaterials will work closely with RUA Medical and other licensees to promote the wider use of Elast-Eon(TM) in medical devices. RUA Structural Heart Following Completion, AorTech Heart Valve Technologies Limited, a non-trading subsidiary of AorTech, will change its name to RUA Structural Heart and it is planned that it will hold the intellectual property relating to the Company's synthetic heart valve. It is currently planned that RUA Biomaterials will exclusively license its intellectual property in this field to RUA Structural Heart on normal commercial terms, thereby generating royalty income. In future, it is intended that RUA Structural Heart will enter into a commercial agreement with RUA Medical to manufacture the synthetic heart valve utilising a novel manufacturing process and valve design, the IP of which will reside in RUA Structural Heart. RUA Structural Heart has the opportunity to transform the global treatment of heart disease by delivering a synthetic heart valve that will be durable, so reducing the need for future replacement, and should not require lifelong drug treatment. As well as these potential clinical advantages, the manufacturing costs of a synthetic valve are expected to be considerably less than those of current valve technology making this a potentially disruptive advance in heart valve surgery. When it initially developed a synthetic valve, AorTech was ahead of the market. The Directors believe that the global heart valve market (valued at some US$4.8 billion in 2017 ([1]) and forecast to reach US$8.8 billion in 2022 ([2]) ) is now in need of new technology, enhancing the opportunities available to AorTech.
someuwin
11/3/2020
08:24
"Progress has been good, and it is anticipated that animal trials for large bore vascular grafts will commence in the coming months as part of the regulatory testing necessary to obtain approval to market those devices."
someuwin
11/3/2020
07:44
Excellent news Gla
andyview
11/3/2020
07:43
Fantastic news, there is nothing holding the company back now. Also great that the majority of the cost is in shares at £1 gla
parsons4
11/3/2020
07:43
Yup, the AOR ticker would be sorely missed. TMK
tees maar khan
11/3/2020
07:40
Awesome news, thought this could be on the cards one way or another at some stage given the close operational relationship between the two. Confidence boosting price for new shares issued on all fronts not least from the seller. This set us up for a fascinating few months. GLA.
greedy rooster
11/3/2020
07:38
Will the ticker change? Sad to see AorTech name going.
the stigologist
11/3/2020
07:11
Highlights · Acquisition of a profitable, cash generative, full-service medical device developer and manufacturer that provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class 7 and 8 cleanroom suites · Cash element of the consideration will be satisfied from the Company's existing resources · The Consideration Shares are being issued at a price of £1.00 per share, a premium of 34.2 per cent. to the Closing Price on 10 March 2020 · Vertical integration of the business, by providing the people, premises and processes necessary to convert the Elast-EonTM polymer into Elast-EonTM products · The Acquisition effectively internalises the Company's manufacturing process, obtaining a large amount of manufacturing know-how and will be able to increase the gross margin potential of its patches and graft products · Shareholder approval is required for the Acquisition · Change of name to RUA Life Sciences plc · Immediately following Completion, it is proposed that David Richmond, a Non-Executive Director of the Company and sole shareholder of RUA, will become Group Chief Executive Officer
landy90
11/3/2020
07:08
That defines strategic,
landy90
09/3/2020
08:35
To be fair, the MM’s set those prices pre-market so the 200 share seller had little choice on price. My online broker accounts were all frozen up on open. I wonder why? That always happens on crash days!
bones
09/3/2020
08:29
Great markets these, £140 trade moves market cap £750,000.....
landy90
07/3/2020
13:24
Thanks Landy90. Good to see RUA being given a professional promotional outing. Any idea how that is being distributed amongst the industry that needs to know?
bones
07/3/2020
10:51
A bit of detail on AorTechs development partner RUA Médical hTTps://ql.mediasilo.com/#ql/5e414a23e4b0e36b7d81ea28/6c5d85ee-c48b-4906-ba84-f440cbb58b50
landy90
06/3/2020
18:13
There is tumbleweed bouncing across this thread......I imagine everyone has got bored with the dull market. However, for those holders that persist in selling little amounts daily and crucifying the share price because the market makers see them coming, did they not read this?: https://www.equitydevelopment.co.uk/edreader/?d=%3D%3DQM5YjM On a separate subject, I follow a few investor types on twitter but I’ve had to unfollow several lately as they insist on retweeting so much unrelated dross that they find personally amusing (I guess). It’s a struggle to find true gems within a landfill site but the retweet function makes it so! Enjoy the weekend :)
bones
05/3/2020
15:58
I agree, GR. It would be market positive for there to be a tangible commercial advancement in the grafts and patches development process beyond the production of an initial prototype, notwithstanding that even that prototype development has been a remarkable achievement by RUA Medical on Aortech’s behalf as partner. I believe there is a lot else also on the burners and hopefully news flow will be a regular feature going forward. Last year, there was no trading update until May 2019 in respect of the year that ends on 31st March. Maybe there will be something closer to the year end this time given there is now so much in progress to report upon.
bones
05/3/2020
13:48
I would like to think that we must be close to the ISO issues for the textile business which i understand will be required before testing. Next update should bring the market up to speed with where this is heading.
greedy rooster
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200710 17:27:09